By taking into account the clinical stages, we found that DLGAP1-AS1 was higher in IDH1 wildtype tumor than in IDH1-mutant tumor samples in WHO II, WHO III, and WHO IV patients (Figure 4(c)). The gene discussed is DLGAP1; the disease is neoplasm.